Discussion page for Arch Therapeutics (ARTH)This page is for discussion of Arch Therapeutics (ARTH).
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Anybody see presentation yesterday. Anything new?
A ton of new stuff. Don’t miss it. https://www.veracast.com/webcasts/bio/ceoinvestor2019/33121486228.cfm?db=0.7073717013304248
excellent and encouraging presentation. Thanks
Interesting, they seem to be primarily focusing on the commercialization of the tropical wound product for the rest of this year. TN did not mention anything about partnering in this area. That is a little concerning as to commercialize requires money. And although he mentioned the IDE in 2019, no mention of what quarter, which in my Project Manager mind means Dec of this year. But at least progress was made in 2018, let’s hope it continues.
Duh – topical not tropical, I guess I have Kauai on my mind.
I am beginning to lose all confidence in Norchi, and it looks like the market feels the same way!!
What did you hear in the BIO presentation that made you begin to lose confidence in Norchi?
$ARTH way-too-Long
Did anybody else hear sincere enthusiasm and confidence in Norchi’s voice? as far as i’m concerned, that was probably the best presentations Norchi’s given in long time. Almost sounded like he was relieved.
Might be the accelerated/narrow time frame too, but he could squeeze all the important points, including advancing in biosurgical program. i’m also quite impressed about the fact that they’ve (finally) implemented broader spectrum of AC5 topical indications in to their strategy – Dermal Sciences is a good start AND sounded very deeply thought of. Next stops are eye diseases and inflammations, right?
I’d say good work during 2018. Now get us the distributor/partner and off we go with uplisting too.
$ARTH – Arch Therapeutics to Provide Corporate Update at the 31st Annual ROTH Conference
https://ir.archtherapeutics.com/press-releases/detail/523
ARTH long
$ARTH – Arch Therapeutics Announces Attendance at 2019 Symposium on Advanced Wound Care Conference (SAWC) and Release of a New AC5TM Topical Gel Video
https://ir.archtherapeutics.com/press-releases/detail/524
$ARTH long
Thought Arth was finally making a move yesterday, but back down again today. Norchi has to know he is running out of money soon. Can’t believe they can’t push this product faster. Anybody watch the latest videos showing the skin graph on a pig. Product worked well, not sure why they didn’t show after wound had healed and comment on if it healed quicker with ac5.
@yelpik Yes, why can’t they roll out AC5 in whatever format faster? Don’t suppose it’d be productive to call Investor Relations and ask questions.
Do you think there are still many of us $ARTH investors on this forum? I still believe in the product and really don’t want to sell – yet.
$ARTH – long in several accounts
$ARTH – obese and long
Have to admit, I’m disappointed at the glacial pace this company moves at. Hanging in there though. I too believe in the product and it’s potential to greatly enhance my bottom line.
Cheers – Todd
$ARCH Also long and waiting. Would love to hear from our numbers man!
I saw the pig presentation….however being in the medical field myself…the bleeding was not excessive enough to be stopped by a normal pressure dressing alone. Now if it could stop arterial bleeding …that would be note worthy and more valuable.
@kentrader On the company’s website, in their promotional material, they say, under Platform – Innovative Technology “Versatile. In animal studies, the material has been applied in a number of applications including brain, spinal cord, femoral artery, liver, or skin of mammals.”
Doesn’t actually say the femoral artery is actively bleeding.
ARTH posted a video two or three years ago showing AC5 stopping arterial bleeding in a pig. KSS wrote about it several times.
I’ll let you guys know when I sell because that is a 100% guarantee the when the stock will soar. I think we have all seen this before https://www.youtube.com/watch?v=h7Ww805tUS8
surgical glue for internal use that they must use light on. Cleveland you still hanging out? I see your name on Bio Pub has the good schizoid doc KSS welcomed you back? Better not sneeze or you are back out. I pray for all us last hanger on’ers that ARTH takes off soon.
From what I heard he is not allowed to talk about ARCH anymore if he wants to stay in KSS’s good graces so little chance of him appearing on these pages.
You took the words right out of my mouth (or off my keyboard), @yelpik. $ARTH is not in Dr KSS’s good graces any more, but, like a obstreperous teenager, I’m doing my own thing.
However, when I sell, I too will tell this board so that you can benefit from the ensuing explosion upwards in price. Actually I’m still hanging on for a buyout by some wealthy pharmaceutical company.
I believe Hedy1234 is still around on both boards. He’s another one of the ones I miss here. They can’t really comment on what is on the good doctor’s site as it’s for paid subscribers, and it’s undoubtedly too difficulty to separate those conversations from our conversations. My own issue too.
Pity we can’t PM people here.
Since the good Doc explained why he was selling here, with the caveat he would let us know if he got back in (which I never saw that he did), is there a reason why such a discussion is/would be considered verbotten?
Dr KSS wouldn’t come back to this site to let us know if he were getting back into $ARTH as he’s totally leading the BioPubKSS site now and his comments there are proprietary.
However, from verbal explosions he has made toward questioners, you might gather that he is, like so many of us, exasperated mightily with the almost total lack of progress by Arch Therapeutics management in bringing this much-needed product to market.
Also it appears that Arch Therapeutics management does not welcome contact from him (and probably anyone on his BioPubKSS team) regarding trying to find out more information or offering advice.
I don’t think I’m stepping on any proprietary toes with this description.
If I’ve got it wrong, let me know!
The problem here is we are hearing only one side of the story. I am sure there is a lot jucy details behind the scenes that we’re not privy to and the result of the falling out between KSS and Cleveland. I have personally experienced the “kindness” of the “good doctor” myself so I can imagine what Norchi felt if he was treated the same way and why he has decided to cut off any communication with KSS. I am not defending Arch in any way by the way – it starts to look more and more like another small biotec failure where only officers of the company benefit.
Whack job? Cleveland come back where you are appreciated. I enjoyed the Doc’s columns, but I’m still holding on to a bunch of his stocks and all are still in the red. He may know science, but he doesn’t know anything about investing. Most of those stocks are so far away from making money that you can wait 5 years and still buy them for what they are priced at today. More losers than winners that would make bio pub no different than the rest of the investment newsletters.
That is “investing” in biotech in essence for you. Now that he has started pushing even smaller penny stock preclinical companies it’s going to get worse. It’s best to realise it closer to gambling and allocate small part of your portfolio for these stocks to satisfy, what Travis calls, “your inner gambler”.
@yelpik What are you still holding?
For the heck of it, let’s compare redness. And you too @analog68, @arch1, @blackngold63, @bpavlich, @brahmsennobles, @Cleveland, @deanbob, @denno, @biotechsucks, @DR bonz, @Dsp, @finventurer, @griffin, @jerome50, @JohnM, @larry C., @rlamore, @toddba, and @tfris.
Sorry if I’ve missed anyone out. Got to head out in a minute.
I have reduced my holdings with some stocks, but still hold quite few. Rather than buy new companies, I’ve been putting sales proceeds into dividend-earning stocks. (Yeah, age is creeping up on me.)
Let’s see how those two sections of my portfolio fare.
Penny
I am still holding quite a bit. And still optimistic. If that makes any sense.
I am still holding quite a bit as well that I had bought in the pre .20cent days. ARTH, AUPH, APTO are my main hold-overs.
Hi, I started following KSS here, and moved over to BioPub as well. I have substantial positions in over a dozen of his “picks” and still have faith in many of them, particularly $APTO, AUPH, $MRKR, $ONCY, $AZRX, and $CWBR. However, KSS is a man-child, prone to tantrums and juvenile rantings, and as I have discovered over time, has absolutely NO financial acumen. Then again, I guess I shouldn’t judge, based on my biotech track record. I do believe KSS gets the science better than just about anybody, but not sure he gets the human analysis (ie reading management and peers), let alone basic financial analysis.
I think you hit nail on the head with your assessment. He claims to be investing in biotech for years yet he doesn’t have any money. I really think the only way to make money in biotech is either to start one and pay yourself a nice salary from selling the stock to naive / greedy investors hoping to make a big profit quickly or to start your own newsletter and charge a subscription fee. Both seem to have no real life consequences if you screw up or are a fraud.
Here’s what I still hold, with current loss/gain:
$ARTH -34% overweight; waiting . . .
$AUPH -2% have sold off most in past couple of months
$CAPR -81% very small token holding
$CWBR -45% something is starting to happen here
$DMAC -32% I didn’t like the reverse stock split
$ESPR -15% plan to sell as soon as it goes up again (ha ha)
$ZFGN -27% very small token holding; still hoping
And . . . $APTO +48% something is in the black!
I am glad I sold most of my biotech stocks, at a loss but would have been an even bigger loss now. I have a tiny position in $FCSC, small short position in $DMAC and a significant (for me) long position in $AUPH which is pretty much the only bio stock I have faith in (20 % in the black at the moment). Do you agree with this sentiment change about $AUPH? What’s not to like here? On the other hand seems like you can make some money by shorting biotech right now. $CWBR looks to good to be true in my opinion (eg. cure for everything) and the situation with the CEO position is alarming. I have a feeling this is going to be another KSS’s dud. If it wasn’t for $HALO options (best trade I ever made) and $AUPH I would be deep in the red.
I still hold: ARTH -20%, CLRB -85%, CWBR -50%, SCYX -50%, TTOO -60%
Overall I am close to breaking even on the biotech adventure and am holding fairly small amounts of all except ARTH.
Yeah in my case “investing” in biotech is not worth the hassle of staying up to date with all developments and sleepless nights if you’re sitting on a fairly big position.
I finally sold my clrb at a great loss; as a matter of fact I sold off most of my losers recently after facing the obvious fact that biotec was a mostly losing game (for me). My winners…even the large ones, did not
nearly make up for my losses. I still have quite a bit of ARTH although I did sell over half….I think Norchi is taking us all for a ride or this drug would be on the market by now; however, I still have hope! I also have kept my TTOO and SCYX thinking there is still a lot of potential for them. I also have REPH as well as dmac, cwbr, auph, apto, oncy and a few others I can’t recall at this time. I plan to buy no more biotech and gradually phase out of that sector in my portfolio. It’s my own fault I have lost so much; I am naturally an optimistic person and invested way too much.
Well, speak of the devil. $ESPR has gone up $5.03 (as of this moment), and I’m down only 5% now. What gives? (I’m not complaining, but am hovering over the SELL button.)
5:33 pm ET May 5, 2019. Esperion (NASDAQ: ESPR) announced today that the U.S. Food and Drug Administration (FDA) has accepted both New Drug Applications for bempedoic acid and the bempedoic acid / ezetimibe combination tablet for filing and regulatory review. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet were developed to be complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C) who need additional LDL-C lowering despite the use of currently accessible therapies.
The PDUFA (Prescription Drug User Fee Act) goal date for the completion of the bempedoic acid NDA review is set for February 21, 2020, and the PDUFA goal date for completion of the bempedoic acid / ezetimibe combination tablet NDA review is set for February 26, 2020. These dates are consistent with our expectations and reflect the standard review period. The FDA has communicated that there is no current plan to hold an advisory committee meeting to discuss the applications.
@tomn Thank you for that interesting update on $ESPR. Bempedoic acid rides again! I’ve taken my finger off the SELL button – for the time being.
Penny
Why have people soured on $AUPH?
Why do you think that people soured on $AUPH?
I have found a very interesting biotech. Senestech: ticker. SNES
They are EPA approved for controlling rodent populations through birth control, no poisons. Already deployed in major US cities and going global. Do your DD and I think you’ll agree this company has the potential for exponential growth.
@milkhom $SNES
Why do you think this company has the potential for exponential growth? What do you personally like about them?
Do you hold shares? (We usually indicate if we are long a particular stock, and what sort of a holding we have (nibble, introductory, half, full, overweight, and the like). No actual share quantities of course.)
Sorry, s/be @milkhon
My only holdovers are as follows:
ONCY small to moderate position -40%
DMAC small to moderate position -52%
ARTH overweight position -16%
APTO moderate position -5%
So it’s all red for Old Doc Bonz.
ARTH has always been my bottom of the 9th, two outs, swinging for the fence stock. If it ever makes contact, I’ll have a nice addition to my retirement. If it gets called looking at the 3rd strike, oh well.
I too am amazed at the inactivity and lack of any type of urgency on the part of this company. It seems that nothing ever happens in the world of ARTH.
I also am very disappointed by how everyone who touted this company as if it was the second coming has stopped or forbidden any mention of it. I understand how Doc KSS lost faith and confidence in the company but for those that he influenced (I understand that we are all responsible for our own due diligence and our own purchases) I wish it could at least still be discussed without a major conflict.
I’m a member at BioPub but I don’t want to even mention ARTH there since it caused such a mess over here. I wish Cleveland could still at least occasionally cover it since he was the ARTH all American cheerleader before moving to Docs new site.
Great to hear from you @drbonz. I miss all our old corespondents in the Gummune.
Don’t know how I lucked out to be in the black on $APTO!
I also am a member of the BioPub but my (paid) membership is expiring and I’m seriously considering not reupping.
$ARTH (and its officers) is definitely in the poo, so to speak, over there, and I don’t want to have strips torn off my (electronic) hide for bringing it up.
Like so many others, I still feel that the product has merits par excellence, and it is so difficult to fathom why things aren’t moving.
When I think of the older family & friends I know and have known who are on blood thinners and suffer nasty bleeding from cuts and nose bleeds, even the use of AC-5 for these relatively simple bleeds would make it worth buying for a gazillion home first aid kits, not to mention the really serious applications in ambulances, emergency rooms and operating theatres.
And I’m reminded of the kids in my care who, in the glorious days of summer vacation, came off their bikes, horses or skateboards, or who hit their heads on something hard or sharp, or the one who vaulted over an empty glass aquarium (not successfully) or the granddaughter who put her hand down on the ice as her mother skated by . . . There’s also the dogs & horses who did strange things that needed first aid. If the product had been around, I’d have been a definite repeat customer already! (PS I’m not afraid of the sight of blood.)
Does anyone out there want to talk to Arch Therapeutics Investor Relations Department on behalf of us Gummies?
Penny
I also have major losses in biotech and plan to get out of this sector altogether. The ony company I have made any money on to date is ESPR. Still holding a bunch of stocks hoping for recovery – plan to sell them all at the opportune time.
So already quite a few here have exactly the same experience. I wonder who are these people that benefited from these biotech “tips” (he doesn’t give investment advice but everyone buys the picks regardless) and bought their “Arth island”. We are obviously doing something wrong.
ARTH DUNNYDAME I was a member until sometime in April Dr KSS is not in Arth or plan to get in. There is something bad wrong there. Its being worked by a couple of con men.
Thomas- I don’t know if we can definitively say that the people running the Company are con-men or if anything is wrong- especially since there is no direct contact. That is is just current opinion based on conjecture, personal issues and unhappiness with the pace of progress. At 1 point just a few years back, these men were the smartest people on the face of the Earth. Given the track record of most Bio-techs, I doubt we can definitively say much at all. These men do have an approval from the FDA, most likely soon a CE mark and have defended their intellectual property vigorously. However…… Look at AKAO recently declaring bankruptcy just a short while after launching a successful new antibiotic that was to be the bees knees according to many here. Seems tough to win even after you appear to win. I am willing to wait although I am a bit uneasy about funding near-term. Cheers- Joe
Today $CWBR filed Form 8-K with the SEC. It’s interesting reading. Confirms that trials are restarting after being temporarily ceased.
Filing/4477010. I’m trying to find the direct link to post here as I had reached the Form 8-K via SeekingAlpha
From Lululeman: I did want to remind everyone that things changed when Avtar joined ARTH. He is a known shyster…….everyone was concerned abut his history but KSS felt Norchi would keep him in tow.
I think they are bleeding ARTH dry with their 350K salaries…if there is funding you can bet a new video will be out and these jokers will keep doing the same!!
Get out on the next run!
$ARTH
3M to Buy Wound-Care Company
Deal for Acelity has a total enterprise value of about $6.7 billion
https://www.wsj.com/articles/3m-to-buy-acelity-for-enterprise-value-of-6-7-billion-11556795031
By Colin Kellaher
Updated May 2, 2019 10:46 a.m. E
Hey Cleveland,
Any expectations as to how this will affect $arth?
Cleveland. I have always liked your analysis and comments on ARTH as you seemed to know more than anyone regarding this company. We here that still hold ARTH shares would truly appreciate it, if you could once again give us the latest on this thing. I don’t want to bring it up over at Biopub since I don’t want to start another stir like we had here. Thanks for your help in the past.
Doc As I said several months ago to you is that Dr. Norchi will talk to you directly as a fellow doctor. Why not get answers from him?
617-431-2316 Please share what you find out. Thanks.
Thank you. Your input is always appreciated – no matter where.
Interesting. Acelity owns Nexcare.
IMHO $ARTH would be a complementary business for 3M ($MMM) to buy out, though financially it looks like they’d better let the dust settle on the Acelity transaction first.
Thanks for posting #Cleveland.
Cleveland thanks for $DMAC unfortunately I got out too soon. Here’s one for the doc $ASX:IBX it’s another medical device. They worked with our national labs to create iron pellet of specific size coat it with a bio coating that attaches to cancer. Then an MRI like device will tell where every cancer that pellet has attached.
Daniel L. Kapp
MD Chief of Surgery, Palm Beach Gardens Medical Center
Board Certified Plastic Surgeon
Director Jupiter Wound Care
http://www.drdanielkapp.com/meet-dr-kapp.php
“The video illustrates the use of AC5TM Topical Gel in porcine surgical wound models of a skin graft (harvest and placement) and of incisions made in the presence of the anticoagulant heparin. Dr. Daniel Kapp, Chief of Plastic Surgery at Palm Beach Gardens Medical Center and advisor to Arch, performed the demonstrations and narrated the video.”
https://ir.archtherapeutics.com/presentations/view/28/demonstration-of-ac5-topical-gel-in-porcine-full-thickness-surgical-wound-models
https://ir.archtherapeutics.com/press-releases/detail/525
Dilution…
$arth
$ARTH Summary of the above by Seeking Alpha:
Arch Therapeutics prices $2.8M registered direct offering
May 13, 2019 8:48 AM ET|
About: Arch Therapeutics, Inc. (ARTH)|
By: Mamta Mayani, SA News Editor
Arch Therapeutics (OTCQB:ARTH) has priced its registered direct offering of ~8.6M units for gross proceeds of ~$2.8M.
Each unit consists of a Common Share, and a Series H Warrant to purchase one common share for the combined price of $0.325 per unit.
The Series H Warrants have an exercise price of $0.40 per share and are exercisable for a period of five years.
Closing date is May 14.
There goes the neighborhood. Down to .29. And the red tide continues.
@drbonz As they say , OMG!
I just looked and $ARTH was .28. Deep sigh.
In a report released today, Michael Higgins from Ladenburg reiterated a Buy rating on Arch Therapeutics Inc (ARTH – Research Report), with a price target of $1.25. The company’s shares closed yesterday at $0.28, close to its 52-week low of $0.27.
Higgins wrote:
“We expect the next months to be equally, if not more productive, as we believe European approval is likely by May 28 and we look for regulatory feedback from management on its next candidate, AC5 Surgical Hemostat, being developed for its most valuable indication(s), internal surgical procedures. We believe management is conducting in 2Q’19 pre-IDE meetings with the FDA to design clinical trials that will test this new device in likely several surgical procedures. We anticipate such plans (including the as-of-yet undisclosed, specific surgery types) to be disclosed in coming months, followed by trial initiations ~YE’19.”
Today $ARTH is valued at its EV/shares value, 48.4M/173.6shares = 0.2788 according to Schwab. My first reaction was “What the hell?” especially because it dropped on the exact same day the market tanked on the China trade news. Upon examining the cause more carefully I realized that five “accredited investors” just contributed in the neighborhood of $545K each (or some variation thereof) to the continued development of the company. These folks are not dumb and don’t throw money around without due diligence. Last time $ARTH hit bottom (~0.27) I bought more, thus lowering average cost. If all goes well I’m now looking at a 5-bagger or more. As we all know, penny stocks are a wild speculation, but I believe (faith is a wonderful thing) this one has the potential. Hold on, Snoopy.
At last, a voice of reason on this thread. As for the 5-bagger, in Steve Martin’s “Picasso at the Lapin Agile,” Picasso says: “Look at the stars – millions and millions of stars!” And Einstein replies: “You’re way too low.”
In a similar vein: Tonto and the Lone Ranger are sleeping in the desert. L.R. wakes up and shakes Tonto and says “Look up at the sky! Isn’t that a wonderful sight? Billions of stars and probably trillions of planets and some day we humans may even travel there!!”
Tonto replies “You crazy, KimoSabi. Somebody stole our tent.”
That same joke, with Sherlock Homes and Watson(and with a better pacing )was voted as the ‘funniest joke of all time’ by some British organisation a few years ago.
I noticed on the Schwab site’s research window that Reuters is the only rating agency that even rates $ARTH, and significantly rates it as a “BUY”. It strikes me as unusual that Reuters gives such a high rating to such a small company. I confirmed this on the Reuters site under ARTH.PK – analyst consensus – which shows 2 analysts rating BUY and 2 rating OUTPERFORM and zero for all other ratings (hold, sell, etc.).
Don’t forget to sign in, mobilecc, so you can get credit for your TUs (thumbs ups)!